Stem cell profit rules urged
By Sacramento Bee,
Sacramento Bee
| 01. 24. 2006
Biotech companies that commercialize taxpayer-funded stem cell research would have to plan to sell the drugs at the "lowest available U.S. commercial price" to low-income Californians, a task force recommended Monday to a citizens group that oversees the state's $3 billion stem cell program.
During a four-hour session at Stanford University, the group also recommended that research grant recipients return 25 percent of income they receive from commercially licensing their stem cell breakthroughs to the state's general fund.
In still another break from federal policy that typically governs such "intellectual property" transactions, members suggested that researchers generally seek nonexclusive licenses for their inventions to provide the maximum potential for fast commercial breakthroughs. Typically, private companies seek exclusive rights to develop a product generated from public research funds.
"Three different companies might pursue that technology three different ways," said Dr. Francisco Prieto, a diabetes specialist at Sutter Medical Group in Elk Grove and task force member who supported the idea.
Monday's recommendations could prove a key turning point in a contentious debate over how Californians and the public treasury will benefit...
Related Articles
By Smriti Mallapaty, Nature | 09.11.2024
Under his microscope, Jun Wu could see several tiny spheres, each less than 1 millimetre wide. They looked just like human embryos: a dark cluster of cells surrounded by a cavity, and then another ring of cells.
But Wu, a...
By Antonio Regalado, MIT Technology Review | 08.22.2024
In 2016, I attended a large meeting of journalists in Washington, DC. The keynote speaker was Jennifer Doudna, who just a few years before had co-invented CRISPR, a revolutionary method of changing genes that was sweeping across biology labs because...
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...